^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lunsumio (mosunetuzumab-axgb)

    i
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    Apply
    A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (GO29781) (NCT02500407)
    Phase 1/2
    Genentech, Inc.
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    09/15/2015
    Primary completion :
    05/21/2024
    Completion :
    09/30/2025
    CD20
    |
    Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) (NCT05171647)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    04/25/2022
    Primary completion :
    05/30/2025
    Completion :
    02/28/2027
    CD20 • CD4
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (CO41942) (NCT04246086)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/12/2020
    Primary completion :
    10/15/2028
    Completion :
    10/15/2030
    CD20 • CD4
    |
    CD20 expression
    |
    lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (CO43805) (NCT05169515)
    Phase 1
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/26/2022
    Primary completion :
    03/07/2027
    Completion :
    03/07/2029
    CD20
    |
    CD20 expression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05672251)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/02/2024
    Primary completion :
    04/22/2025
    Completion :
    04/22/2025
    CD20
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06015880)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    05/20/2024
    Primary completion :
    06/29/2026
    Completion :
    06/29/2026
    IFNG • CD79B • CD4
    |
    CD79B expression
    |
    lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (NCT05615636)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    04/28/2023
    Primary completion :
    08/19/2025
    Completion :
    08/19/2027
    CD20
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo) (NCT04712097)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    10/27/2021
    Primary completion :
    08/25/2025
    Completion :
    05/01/2029
    CD20
    |
    Rituxan (rituximab) • lenalidomide • Lunsumio (mosunetuzumab-axgb)
    Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma (NCT06249191)
    Phase 1/2
    OHSU Knight Cancer Institute
    Not yet recruiting
    Last update posted :
    06/03/2024
    Initiation :
    05/31/2024
    Primary completion :
    04/01/2026
    Completion :
    04/01/2027
    MYC
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Lunsumio (mosunetuzumab-axgb)
    Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (GO40554) (NCT03677154)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    05/23/2019
    Primary completion :
    08/03/2025
    Completion :
    08/03/2025
    CD20
    |
    Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) (NCT05207670)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    02/01/2022
    Primary completion :
    07/31/2028
    Completion :
    07/31/2028
    CD20 • CD4
    |
    CD20 expression
    |
    Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
    Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma (NCT05412290)
    Phase 1
    Washington University School of Medicine
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    12/22/2022
    Primary completion :
    07/31/2027
    Completion :
    06/30/2029
    CD20
    |
    Lunsumio (mosunetuzumab-axgb)
    Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NCT05886036)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/29/2024
    Initiation :
    01/23/2024
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    CD20 • PD-1 • PD-L2
    |
    CD20 expression
    |
    Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Lunsumio (mosunetuzumab-axgb) • Mabtas (rituximab biosimilar)
    A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma (NCT04313608)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/25/2024
    Initiation :
    06/04/2020
    Primary completion :
    10/26/2021
    Completion :
    10/26/2021
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (BrUOG 401) (NCT04792502)
    Phase 2
    Brown University
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    07/14/2022
    Primary completion :
    08/01/2025
    Completion :
    08/01/2027
    CD20
    |
    CD20 expression
    |
    lenalidomide • Lunsumio (mosunetuzumab-axgb)
    A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma (GO40515) (NCT03677141)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/06/2024
    Initiation :
    03/08/2019
    Primary completion :
    10/12/2023
    Completion :
    10/12/2023
    CD20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • cyclophosphamide intravenous
    A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (NCT05961696)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    10/10/2023
    Initiation :
    07/05/2023
    Primary completion :
    10/03/2023
    Completion :
    10/03/2023
    CD20
    |
    CD20 expression
    |
    Lunsumio (mosunetuzumab-axgb)
    Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma (MARSUN) (NCT06006117)
    Phase 3
    The Lymphoma Academic Research Organisation
    Recruiting
    Last update posted :
    09/27/2023
    Initiation :
    09/05/2023
    Primary completion :
    09/01/2027
    Completion :
    09/01/2032
    CD200 • ITGAX
    |
    CD200 expression
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • Lunsumio (mosunetuzumab-axgb)